Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ARIPIPRAZOLE vs BREVITAL SODIUM
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Partial agonist at D2 and 5-HT1A receptors; antagonist at 5-HT2A receptors.
Brevital sodium (methohexital) is a barbiturate that acts as a GABA-A receptor agonist, enhancing chloride ion influx and hyperpolarizing neurons, leading to rapid sedation and anesthesia.
Schizophrenia,Acute manic and mixed episodes associated with bipolar I disorder,Maintenance treatment of bipolar I disorder,Adjunctive treatment of major depressive disorder,Irritability associated with autistic disorder,Tourette's disorder
Induction and maintenance of general anesthesia,Adjunct to regional anesthesia,Short-duration surgical procedures
Oral: 10-15 mg once daily; initial and target dose 10-15 mg; maximum 30 mg/day. IM: 9.75 mg single dose, then 5.25-9.75 mg every 2 hours if needed; maximum 30 mg/day.
Induction of anesthesia: 1-1.5 mg/kg IV bolus over 15 seconds; maintenance: 0.5-1 mg/kg IV bolus as needed or 50-150 mcg/kg/min IV infusion.
Aripiprazole has a terminal elimination half-life of approximately 75 hours in extensive CYP2D6 metabolizers and about 146 hours in poor metabolizers. The active metabolite, dehydro-aripiprazole, has a half-life of about 94 hours. This long half-life allows for once-daily dosing and gradual achievement of steady state (14 days in extensive metabolizers).
Terminal elimination half-life: 3–6 hours (mean ~4 hours); prolonged in hepatic impairment, obesity, or with repeated dosing due to redistribution.
Primarily hepatic via CYP2D6 and CYP3A4.
Hepatic metabolism primarily by CYP2C9 and CYP3A4 to inactive metabolites; less than 1% excreted unchanged in urine.
Aripiprazole is extensively metabolized primarily by the liver via CYP2D6 and CYP3A4. Approximately 25% of the dose is excreted unchanged in urine, and about 55% in feces. The major metabolite, dehydro-aripiprazole, accounts for about 40% of the AUC and is also excreted in urine and feces.
Primarily hepatic biotransformation to inactive metabolites (mainly hydroxy-methohexital), with renal excretion of metabolites; less than 1% excreted unchanged in urine. Minor biliary/fecal elimination.
Aripiprazole is >99% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein. High protein binding means that changes in protein levels (e.g., hypoalbuminemia) can affect free drug concentration.
Approximately 70–90% bound to albumin.
The volume of distribution (Vd) for aripiprazole is approximately 4.9 L/kg, indicating extensive tissue distribution (well beyond total body water). This large Vd suggests significant partitioning into tissues, which contributes to the long half-life.
Vd: 1.1–2.5 L/kg (mean ~1.5 L/kg). Larger Vd indicates extensive tissue distribution (highly lipophilic), leading to rapid redistribution and short duration after single bolus.
Oral: The absolute bioavailability of aripiprazole tablets is approximately 87%. Bioavailability is not significantly affected by food. Intramuscular immediate-release: Bioavailability is 100% for the IM formulation relative to oral. The long-acting injectable (aripiprazole lauroxil) has a bioavailability of about 100% compared to oral aripiprazole after reaching steady state.
IV: 100%. IM: Not well established; likely >90%. Rectal: Variable, ~50–70% due to first-pass metabolism and incomplete absorption.
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥15 m L/min). For severe renal impairment (Cr Cl <15 m L/min), use with caution; limited data suggests no adjustment needed, but monitor tolerability.
No dosage adjustment required for GFR ≥10 m L/min; for GFR <10 m L/min, reduce dose by 50%.
Child-Pugh Class A (mild): no adjustment. Child-Pugh Class B (moderate): start at 10 mg/day; titrate cautiously. Child-Pugh Class C (severe): avoid use; if unavoidable, start at 5 mg/day and titrate slowly.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: reduce dose by 75% or consider alternative.
Schizophrenia (≥13 years): 10-15 mg/day initially; target 15 mg/day; max 30 mg/day. Irritability associated with autistic disorder (6-17 years): 5-10 mg/day; start at 2.5 mg/day for ≥30 kg and 5 mg/day for <30 kg; titrate gradually. Tourette's disorder (6-18 years): 5-10 mg/day; start at 2.5 mg/day for <50 kg and 5 mg/day for ≥50 kg; max 10 mg/day.
Induction: 1-2 mg/kg IV; maintenance: 0.5-1 mg/kg IV bolus or 50-150 mcg/kg/min IV infusion. Contraindicated in infants <2 months with stable BSA.
Initiate at 10 mg/day; titrate slowly due to increased sensitivity and risk of hypotension, sedation, and extrapyramidal symptoms. Maximum 15 mg/day in elderly patients with psychosis. Consider lower initial doses (2-5 mg/day) in frail patients.
Reduce induction dose by 50% and administer slowly over 60 seconds; maintenance infusion rates at lower end (50-100 mcg/kg/min).
Increased risk of death in elderly patients with dementia-related psychosis.
None.
Increased risk of cerebrovascular events in elderly with dementia, neuroleptic malignant syndrome, tardive dyskinesia, metabolic changes (hyperglycemia, dyslipidemia, weight gain), orthostatic hypotension, leukopenia/neutropenia, seizures, cognitive and motor impairment, and body temperature dysregulation.
Respiratory depression and apnea may occur; resuscitative equipment must be available,Hypotension and bradycardia possible; use with caution in patients with cardiovascular disease,Extravasation causes tissue necrosis; avoid intra-arterial injection,Seizures may occur in epileptic patients,Rapid injection may cause severe respiratory depression
Hypersensitivity to aripiprazole or any components of the formulation.
Known hypersensitivity to barbiturates,Porphyria (may precipitate acute attacks),Severe respiratory insufficiency,Status asthmaticus,Hypovolemic shock or severe hypotension
No significant food interactions. Absorption unaffected by food. Avoid grapefruit juice as it may increase aripiprazole levels via CYP3A4 inhibition.
No specific food interactions are documented for BREVITAL SODIUM. However, patients should avoid heavy meals before anesthesia due to risk of aspiration. Do not consume alcohol or grapefruit juice for 24 hours before and after administration, as they may alter drug metabolism and increase sedation.
First trimester: Limited human data; animal studies show no teratogenicity at therapeutic doses, but increased risk of neural tube defects at high doses. Second/third trimesters: Possible risk of extrapyramidal symptoms or withdrawal in neonates; risk of gestational diabetes and weight gain. Overall, not a major human teratogen but risk-benefit assessment required.
Teratogenic potential not fully established in humans. In animal studies, methohexital caused fetal resorptions and malformations at maternally toxic doses. First trimester: Avoid unless essential; risk of neural tube defects cannot be excluded. Second trimester: Limited data, but may cause fetal depression if used near delivery. Third trimester: Crosses placenta; may cause neonatal respiratory depression, hypotonia, and prolonged sedation. Use only if clearly needed with lowest effective dose.
Aripiprazole is excreted into breast milk; estimated relative infant dose is 1-8% of maternal weight-adjusted dose. M/P ratio not established. Monitor infant for sedation, poor feeding, and extrapyramidal symptoms. Consider benefits of breastfeeding vs. potential risks.
Excretion into human milk unknown. M/P ratio not determined. Due to short half-life, minimal transfer expected after a single dose. Caution with repeated doses or prolonged infusion. Monitor infant for sedation, feeding difficulties, or respiratory depression.
Increased clearance and volume of distribution in pregnancy may necessitate dose increases, especially in the third trimester. Therapeutic drug monitoring if available; adjust based on clinical response and tolerability. Postpartum, reduce to prepregnancy dose to avoid toxicity.
Pregnancy may increase volume of distribution and clearance, potentially requiring higher initial doses, but the induction dose typically unchanged. Reduced doses may be needed in preeclampsia or cesarean section due to enhanced sensitivity. No specific dose adjustment guidelines; titrate to effect with careful monitoring.
Aripiprazole is a partial dopamine agonist, distinguishing it from typical antipsychotics. Monitor for akathisia, especially during titration. QT prolongation risk is lower than with other antipsychotics, but ECG is recommended in patients with cardiac risk. Tardive dyskinesia risk exists but may be lower than with typical agents. Avoid abrupt discontinuation to prevent withdrawal dyskinesias. Metabolized by CYP2D6 and CYP3A4; dose adjustments needed with CYP2D6 inhibitors or poor metabolizers. May cause orthostatic hypotension; titrate slowly. Weight gain and metabolic effects are less pronounced than with olanzapine or clozapine, but still monitor weight, lipids, and glucose.
BREVITAL SODIUM (methohexital) is an ultrashort-acting barbiturate used for induction of anesthesia and for short procedures. Due to its rapid onset and brief duration, it requires careful titration. It is contraindicated in patients with porphyria. Extravasation causes tissue necrosis; administer only through a secure IV line. It lowers seizure threshold, but can also be used for electroconvulsive therapy (ECT) to induce seizures. Respiratory depression and hypotension are dose-dependent; have resuscitation equipment ready. Avoid in patients with severe hepatic impairment. Coadministration with opioids or benzodiazepines potentiates sedation and respiratory depression.
Take once daily without regard to meals. Swallow tablets whole, do not crush or chew.,May cause dizziness or drowsiness, especially when starting; avoid driving until you know how it affects you.,Do not stop taking suddenly without consulting your doctor, as this may cause withdrawal symptoms.,Report any restlessness, muscle stiffness, fever, or unusual movements to your doctor immediately.,Limit alcohol intake as it can increase side effects like drowsiness.,Inform your doctor of all medications you take, including over-the-counter drugs and supplements.,If you miss a dose, take it as soon as you remember unless it is almost time for the next dose; do not double up.,Regular blood tests may be needed to check for effects on blood sugar and cholesterol.
BREVITAL SODIUM is a potent anesthetic that causes rapid loss of consciousness and should only be administered by trained medical professionals.,You may experience temporary pain or burning at the injection site; report any persistent pain or swelling to your healthcare provider.,Drowsiness, dizziness, and confusion may persist for several hours after the procedure; do not drive or operate machinery for at least 24 hours.,Avoid alcohol and other sedatives for 24 hours before and after the procedure as they may increase side effects.,Inform your doctor if you have a history of porphyria, liver disease, or drug allergies.,If you are pregnant or breastfeeding, discuss the risks and benefits with your healthcare provider.
"Aripiprazole, a partial dopamine D2 and serotonin 5-HT1A agonist, may have its adverse effects potentiated by methsuximide, a succinimide anticonvulsant that inhibits CYP3A4. This can lead to increased aripiprazole plasma concentrations, raising the risk of extrapyramidal symptoms, sedation, and QT prolongation. Clinical outcomes include heightened neurotoxicity and potential for arrhythmias."
"Concurrent use of aripiprazole and clonazepam increases the risk of central nervous system (CNS) depression, including excessive sedation, dizziness, ataxia, and impaired cognitive or motor function. This additive pharmacodynamic interaction results from the combined depressant effects on the CNS mediated by GABAergic potentiation from clonazepam and dopaminergic/serotonergic modulation from aripiprazole. Patients may experience heightened somnolence, psychomotor slowing, and an increased risk of falls, particularly during initiation or dose escalation."
"Aripiprazole, an atypical antipsychotic with partial agonism at dopamine D2 and serotonin 5-HT1A receptors and antagonism at 5-HT2A receptors, can induce orthostatic hypotension, particularly during initial titration. This hypotensive effect may be additive when combined with moexipril, an ACE inhibitor that lowers blood pressure by inhibiting angiotensin II production. Concomitant use increases the risk of symptomatic hypotension, including dizziness, syncope, and falls, especially in elderly or volume-depleted patients."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ARIPIPRAZOLE vs BREVITAL SODIUM, answered by our medical review team.
ARIPIPRAZOLE is a Atypical Antipsychotic that works by Partial agonist at D2 and 5-HT1A receptors; antagonist at 5-HT2A receptors.. BREVITAL SODIUM is a Barbiturate Anesthetic that works by Brevital sodium (methohexital) is a barbiturate that acts as a GABA-A receptor agonist, enhancing chloride ion influx and hyperpolarizing neurons, leading to rapid sedation and anesthesia.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ARIPIPRAZOLE and BREVITAL SODIUM depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ARIPIPRAZOLE is: Oral: 10-15 mg once daily; initial and target dose 10-15 mg; maximum 30 mg/day. IM: 9.75 mg single dose, then 5.25-9.75 mg every 2 hours if needed; maximum 30 mg/day.. The standard adult dose of BREVITAL SODIUM is: Induction of anesthesia: 1-1.5 mg/kg IV bolus over 15 seconds; maintenance: 0.5-1 mg/kg IV bolus as needed or 50-150 mcg/kg/min IV infusion.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ARIPIPRAZOLE and BREVITAL SODIUM in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ARIPIPRAZOLE is classified as Category A/B. First trimester: Limited human data; animal studies show no teratogenicity at therapeutic doses, but increased risk of neural tube defects at high doses. Second/third trimesters: P. BREVITAL SODIUM is classified as Category C. Teratogenic potential not fully established in humans. In animal studies, methohexital caused fetal resorptions and malformations at maternally toxic doses. First trimester: Avoid . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.